In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.42 below Stereotaxis Inc average.

Within Medical Equipment & Supplies industry 154 other companies have achieved higher Quick Ratio than Stereotaxis Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2093 to 2780.

Explain Quick Ratio?
How much Cash & cash equivalents STXS�s has?
What are STXS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

STXS Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	29.15 %	-4.72 %	3.51 %	-1.69 %	69.34 %
Y / Y Cash & cash equivalent Change	61.02 %	37.87 %	9.86 %	-1.47 %	-52.55 %
Quick Ratio MRQ	0.42	0.63	0.6	0.52	0.34
STXS's Total Ranking	# 2780	# 2093	# 1537	# 1998	# 2131
Seq. Current Liabilities Change	16.07 %	3.25 %	9.77 %	-1.82 %	-14.37 %
Seq. Cash & cash equivalent Change	-23.25 %	8.9 %	27.75 %	50.8 %	-34.28 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 155
Healthcare Sector	# 756
Overall Market	# 2780

Quick Ratio Statistics
High	Average	Low
7.07	1.23	0.11
(Sep 30 2023)		(Mar 31 2016)

Financial Statements
Stereotaxis Inc 's Current Liabilities	$ 27 Millions	Visit STXS's Balance sheet
Stereotaxis Inc 's Cash & cash equivalent	$ 11 Millions	Visit STXS's Balance sheet
Source of STXS's Sales		Visit STXS's Sales by Geography

Cumulative Stereotaxis Inc 's Quick Ratio

STXS's Quick Ratio for the trailling 12 Months

STXS Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	6.09 %	9.85 %	30.08 %	54.69 %	108.19 %
Y / Y Cash & cash equivalent TTM Growth	23.02 %	-5.51 %	-24.82 %	-35.84 %	-58.59 %
Quick Ratio TTM	0.54	0.53	0.47	0.46	0.46
Total Ranking TTM	# 4035	# 3199	# 2279	# 3051	# 2857
Seq. Current Liabilities TTM Growth	6.99 %	-1.3 %	0.87 %	-0.4 %	10.78 %
Seq. Cash & cash equivalent TTM Growth	9.34 %	9.68 %	2.99 %	-0.39 %	-16.02 %

Quick ratio ranking by company, industry and sector >> Back to STXS Financial Strength Comparisons >> Go to Compare STXS Quick Ratio to its Competitors

News about Stereotaxis Inc Quick Ratio

Navigating Innovation Stereotaxis and CardioFocus Forge Partnership to Revolutionise Robotic Pulsed Field Ablation fo...

In a strategic alignment borne of necessity and innovation, Stereotaxis (NYSE: STXS), a trailblazer in surgical robotics dedicated to minimally invasive endovascular interventions, announced its collaboration with CardioFocus, Inc., a vanguard in the realm of ablation treatment for cardiac arrhythmias. The Collaboration Agreement, disclosed on October 13, 2025, marks a significant step forward in the realm of cardiac care, propelling robotic Pulsed Field Ablation (PFA) technology towards commercial viability.Stereotaxis, with its illustrious history in surgical robotics, has consistently sought to redefine the paradigms of cardiac intervention. By joining forces with CardioFocus, the partnership aims to harness the intricacies of advanced robotic systems and PFA technology, thereby enhancing the precision and efficacy of arrhythmia treatment. Cardiac arrhythmias remain a pressing global health challenge, affecting millions and often resulting in serious complications. The innovation offered by PFA holds promise, providing non-thermal ablation methods that could mitigate damage to surrounding cardiac tissue, a critical concern in conventional ablation procedures.

On the trailing twelve months basis STXS Cash & cash equivalent soared by 61.02 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Stereotaxis Inc 's Quick Ratio to 0.54, Quick Ratio remained below STXS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 205 other companies have achieved higher Quick Ratio than Stereotaxis Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3199 to 4035.

Explain Quick Ratio?
How much Cash & cash equivalents STXS�s has?
What are STXS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 206
Healthcare Sector	# 902
Within the Market	# 4035

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.03	1.07	0.15
(Dec 31 2020)		(Dec 31 2017)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Establishment Labs Holdings Inc	1.10	$ 71.157 Millions	$ 64.558 Millions
Treace Medical Concepts Inc	1.10	$ 45.619 Millions	$ 41.496 Millions
Resmed Inc	1.05	$ 1,469.234 Millions	$ 1,395.110 Millions
Adagio Medical Holdings inc	1.02	$ 7.740 Millions	$ 7.562 Millions
Plus Therapeutics Inc	1.00	$ 8.587 Millions	$ 8.567 Millions
Pavmed Inc	1.00	$ 4.070 Millions	$ 4.088 Millions
Sonoma Pharmaceuticals Inc	0.98	$ 5.338 Millions	$ 5.447 Millions
Nuwellis Inc	0.98	$ 3.922 Millions	$ 4.008 Millions
Electrocore Inc	0.97	$ 11.543 Millions	$ 11.933 Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________	0.96	$ 10.924 Millions	$ 11.366 Millions
Medline Inc	0.96	$ 2,677.000 Millions	$ 2,803.000 Millions
Neuronetics Inc	0.88	$ 24.947 Millions	$ 28.309 Millions
Orthopediatrics Corp	0.87	$ 45.879 Millions	$ 52.852 Millions
Haemonetics Corporation	0.85	$ 223.384 Millions	$ 263.235 Millions
Lifeward ltd	0.85	$ 9.448 Millions	$ 11.159 Millions
Qhslab Inc	0.84	$ 0.317 Millions	$ 0.376 Millions
Intelligent Bio Solutions Inc	0.84	$ 4.141 Millions	$ 4.935 Millions
Integra Lifesciences Holdings Corp	0.83	$ 274.084 Millions	$ 330.881 Millions
Lifestance Health Group Inc	0.82	$ 225.943 Millions	$ 274.753 Millions
Pro dex Inc	0.81	$ 10.542 Millions	$ 13.086 Millions
Carlisle Companies Incorporated	0.75	$ 665.300 Millions	$ 888.400 Millions
Northview Acquisition Corp	0.73	$ 12.200 Millions	$ 16.622 Millions
Livanova Plc	0.73	$ 516.619 Millions	$ 707.004 Millions
Angiodynamics Inc	0.72	$ 53.864 Millions	$ 74.717 Millions
Rosecliff Acquisition Corp I	0.70	$ 14.000 Millions	$ 19.869 Millions
Innovage Holding Corp	0.69	$ 141.326 Millions	$ 203.891 Millions
Msa Safety Inc	0.69	$ 200.057 Millions	$ 288.899 Millions
Valion Bio Inc	0.69	$ 2.108 Millions	$ 3.046 Millions
Lensar Inc	0.69	$ 13.565 Millions	$ 19.640 Millions
West Pharmaceutical Services Inc	0.68	$ 435.800 Millions	$ 640.500 Millions

Date modified: 2026-09-04T00:11:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.